Analyst Price Target is $15.50
▲ +598.20% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Black Diamond Therapeutics in the last 3 months. The average price target is $15.50, with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 598.20% upside from the last price of $2.22.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Black Diamond Therapeutics. This rating has held steady since March 2023, when it changed from a Hold consensus rating.
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
